0.377
price down icon5.70%   -0.0228
pre-market  Pre-market:  .38   0.003   +0.80%
loading
Bioatla Inc stock is traded at $0.377, with a volume of 660.17K. It is down -5.70% in the last 24 hours and down -4.56% over the past month. BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
See More
Previous Close:
$0.3998
Open:
$0.3953
24h Volume:
660.17K
Relative Volume:
1.09
Market Cap:
$22.02M
Revenue:
-
Net Income/Loss:
$-123.46M
P/E Ratio:
-0.1456
EPS:
-2.59
Net Cash Flow:
$-104.11M
1W Performance:
+1.73%
1M Performance:
-4.56%
6M Performance:
-24.54%
1Y Performance:
-77.95%
1-Day Range:
Value
$0.3718
$0.415
1-Week Range:
Value
$0.3254
$0.415
52-Week Range:
Value
$0.2601
$2.525

Bioatla Inc Stock (BCAB) Company Profile

Name
Name
Bioatla Inc
Name
Phone
858-558-0708
Name
Address
11085 TORREYANA ROAD, SAN DIEGO
Name
Employee
61
Name
Twitter
Name
Next Earnings Date
2025-03-21
Name
Latest SEC Filings
Name
BCAB's Discussions on Twitter

Compare BCAB with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
BCAB
Bioatla Inc
0.377 19.94M 0 -123.46M -104.11M -2.59
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Bioatla Inc Stock (BCAB) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-13-24 Downgrade H.C. Wainwright Buy → Neutral
Sep-15-22 Initiated JMP Securities Mkt Outperform
May-05-22 Downgrade Credit Suisse Outperform → Neutral
Mar-21-22 Initiated H.C. Wainwright Buy
Oct-15-21 Resumed BTIG Research Buy
Jun-28-21 Initiated ROTH Capital Buy
May-05-21 Resumed Credit Suisse Outperform
Apr-26-21 Resumed Credit Suisse Outperform
Jan-11-21 Initiated BTIG Research Buy
Jan-11-21 Initiated Credit Suisse Outperform
Jan-11-21 Initiated JP Morgan Overweight
Jan-11-21 Initiated Jefferies Buy
View All

Bioatla Inc Stock (BCAB) Latest News

pulisher
Jul 24, 2025

What analysts say about BioAtla Inc. stockConsistently high returns - Autocar Professional

Jul 24, 2025
pulisher
Jul 22, 2025

What drives BioAtla Inc. stock priceFree Stock Index Interpretation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

BioAtla Inc. Stock Analysis and ForecastFree Stock Index Interpretation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Now The Time To Buy BioAtla Inc (NASDAQ: BCAB) Stock? - Stocksregister

Jul 22, 2025
pulisher
Jul 22, 2025

Is BioAtla Inc. a good long term investmentHigh-yield market plays - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is BioAtla Inc. stock a good hedge against inflationFree Consultation - Newser

Jul 22, 2025
pulisher
Jul 19, 2025

What analysts say about BioAtla Inc. stock outlookFast Gains With Reduced Risk - beatles.ru

Jul 19, 2025
pulisher
Jul 17, 2025

BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting - The Manila Times

Jul 17, 2025
pulisher
Jul 15, 2025

What makes BioAtla Inc. stock price move sharplyTrending Stock Alert - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why BioAtla Inc. stock attracts strong analyst attentionStable Stocks With High Yield - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How BioAtla Inc. stock performs during market volatilityPortfolio Boosting Stock Alerts - Newser

Jul 15, 2025
pulisher
Jul 08, 2025

BioAtla (NASDAQ:BCAB) Stock Price Up 2.6% – Here’s Why - Defense World

Jul 08, 2025
pulisher
Jul 04, 2025

BioAtla presents Phase I data of BA3182 for metastatic adenocarcinoma - Yahoo Finance

Jul 04, 2025
pulisher
Jun 20, 2025

BioAtla Approves 2025 Corporate Bonus Plan - TipRanks

Jun 20, 2025
pulisher
Jun 14, 2025

BioAtla, Inc. (NASDAQ:BCAB) Shares Purchased by Two Sigma Investments LP - Defense World

Jun 14, 2025
pulisher
Jun 09, 2025

Jane Street Group LLC Purchases 100,204 Shares of BioAtla, Inc. (NASDAQ:BCAB) - Defense World

Jun 09, 2025
pulisher
Jun 09, 2025

BioAtla, Inc. (NASDAQ:BCAB) Stock Position Lowered by Two Sigma Advisers LP - Defense World

Jun 09, 2025
pulisher
Jun 08, 2025

Millennium Management LLC Cuts Stock Position in BioAtla, Inc. (NASDAQ:BCAB) - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

BioAtla (NASDAQ:BCAB) Upgraded by Wall Street Zen to Hold Rating - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

BioAtla presents Phase 2 Oz-V clinical trial data at ASCO 2025 - MSN

Jun 06, 2025
pulisher
Jun 03, 2025

Why Did BioAtla Inc (NASDAQ: BCAB) Drop So Much? - Stocksregister

Jun 03, 2025
pulisher
Jun 03, 2025

BioAtla reports promising trial results for cancer drug By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 02, 2025

BioAtla reports promising trial results for cancer drug - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

BioAtla (BCAB) Showcases Promising Data for Ozuriftamab Vedotin in Key Cancer Trial | BCAB Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen - The Manila Times

Jun 02, 2025
pulisher
Jun 02, 2025

BioAtla's New Cancer Drug Achieves 13x Better Response Rate Than Standard Treatment in Phase 2 Trial - Stock Titan

Jun 02, 2025

Bioatla Inc Stock (BCAB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Cap:     |  Volume (24h):